Kids With Food Allergies is sharing this press release from the 2018 AAAAI/WAO Joint Congress to bring you the latest research news quickly. Three studies were presented about Alpha Gal or Red Meat Allergy.
The atopic march describes how patients who have an allergic disease are more likely to develop another or multiple allergic diseases in their lifetime. This progression commonly starts with eczema in infancy and can develop into food allergy, asthma or hay fever in childhood. Now, new research being presented at the Joint Congress provides evidence that EoE is a late but probable part of this disease progression.
Data presented at the 2018 AAAAI/WAO Joint Congress found that reactions to peanut were the most common cause of anaphylaxis in pediatric intensive care units. Food induced anaphylaxis should be considered a serious medical condition and aggressively prevented and treated.
A study presented at the 2018 AAAAI/WAO Joint Congress found that cow’s milk allergy may negatively affect growth in children up to 12 years old.
As part of a budget plan for 2019, the White House is proposing cutting the value of these cards in half. They want to replace the other half with what it calls “America’s Harvest Box.” This box would have “100 percent U.S. grown and produced food,” made up of staple food items.
DBV Technologies today announced preliminary results from Part B, or Phase II, of a Phase I/II study evaluating the efficacy and safety of three dose regimens of Viaskin Milk (150 µg, 300 µg, 500 µg) in 198 patients for the treatment of IgE-mediated cow's milk protein allergy (CMPA). The MILES (Milk Efficacy and Safety) study was designed to determine a safe and effective dose in two age groups.
Kids With Food Allergies is sharing these press releases from Aimmune Therapeutics and DBV Technologies to bring you the latest research news quickly. [PRESS RELEASE] Aimmune Therapeutics’ Pivotal Phase 3 PALISADE Trial of AR101 Meets Primary Endpoint in Patients With Peanut Allergy BRISBANE, Calif.– (BUSINESS WIRE) – Feb. 20, 2018 – Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced...
The movie "Peter Rabbit" depicts a scene some families managing food allergies might find alarming. Peter and the other rabbits intentionally attack Mr. McGregor with his known food allergen causing him to have a serious allergic reaction, called anaphylaxis (anna-fih-LACK-sis).
The Asthma and Allergy Foundation of America (AAFA) cautions parents raising children with food allergies that some scenes in the newly-released “Peter Rabbit” film may be disturbing for young viewers with food allergies. In the film, a character with a known food allergy to blackberries is attacked with them. This leads to a severe allergic reaction known as anaphylaxis and the need to use a lifesaving injection of the drug epinephrine.
The new movie, Peter Rabbit, has a scene that may be disturbing to young viewers who have a food allergy. We're asking Hollywood to stop using food allergies as a punchline.
Oral immunotherapy (OIT) is a proposed method to treat food allergy. It is currently in late-stage clinical trials (peanut specifically). It is expected to be approved by the U.S. Food and Drug Administration (FDA) soon. There have been many clinical trials for specific food OIT alone and with medicines, such as omalizumab, as reported in this study.
It is safe for ALL people with an egg allergy to get a flu shot, even if you’ve had a severe egg allergy in the past. This includes people who have had anaphylaxis (a severe allergic reaction) to egg.
Combining a 16-week initial course of the medication omalizumab with oral immunotherapy (OIT) greatly improves the efficacy of OIT for children with allergies to multiple foods, new clinical trial findings show. After 36 weeks, more than 80 percent of children who received omalizumab and OIT could safely consume two-gram portions of at least two foods to which they were allergic, compared with only a third of children who received placebo and OIT.
kaléo today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for AUVI-Q® (epinephrine injection, USP) 0.1 mg, the first and only epinephrine auto-injector (EAI) specifically designed for the treatment of life-threatening allergic reactions, including anaphylaxis, in infants and small children weighing 16.5 to 33 pounds (7.5 to 15 kilograms) who are at risk for or have a history of serious allergic reactions.
Q: My son is allergic to sunflower seeds. Without having tried it, would he be also allergic to sunflower oil?